Peter Mesenbrink

机构：Novartis (Switzerland), Novartis (China) · ORCID：0000-0002-5624-6726

发表论文 109 篇 · 总被引 9613 次 · h-index 34

代表论文

• Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL (2023 · EClinicalMedicine · 被引 46)
• Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information (2024 · PLoS ONE · 被引 35)
• A deep-learning-based model for assessment of autoimmune hepatitis from histology: AI(H) (2024 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 被引 17)
• Regulatory Issues of Platform Trials: Learnings from EU‐PEARL (2024 · Clinical Pharmacology & Therapeutics · 被引 16)
• Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression (2025 · ACR Open Rheumatology · 被引 9)
• Developing generic templates to shape the future for conducting integrated research platform trials (2024 · Trials · 被引 8)